openPR Logo
Press release

Huateng Pharma's Featured Product Line: Veterinary API and Intermediates

01-17-2024 08:54 AM CET | Health & Medicine

Press release from: Hunan Huateng Pharmaceutical Co., Ltd.

Huateng Pharma, a Contract Development and Manufacturing Organization (CDMO) specializing in APIs and intermediates, is proud to announce its featured product line catering specifically to the veterinary industry. With a commitment to delivering high-quality solutions, Huateng Pharma offers a comprehensive range of veterinary APIs and intermediates, including Fluralaner (CAS NO.: 864731-61-3) and Sarolaner (CAS NO.: 1398609-39-6).
As a leading player in the pharmaceutical manufacturing sector, Huateng Pharma has established a solid reputation for its expertise and innovation in developing and producing active pharmaceutical ingredients (APIs) and intermediates. The company's veterinary product line represents its dedication to addressing the unique needs of the animal health industry.
Fluralaner, one of the flagship products in Huateng Pharma's veterinary portfolio, is a highly effective API used in the treatment and prevention of various parasitic infections in animals. With its excellent safety profile and rapid action, Fluralaner has gained significant recognition among veterinarians and pet owners alike. Huateng Pharma's Fluralaner is manufactured in compliance with the highest quality standards, ensuring its efficacy and reliability for animal health.
Sarolaner, another key product offered by Huateng Pharma, is an essential API in the fight against fleas and ticks in animals. By providing long-lasting protection, Sarolaner has become a trusted solution for veterinarians seeking effective parasite control. Huateng Pharma's Sarolaner is produced with meticulous attention to detail, ensuring consistent potency and purity.
Mr. Xiong, Sales Director at Huateng Pharma, expressed his enthusiasm for the company's veterinary product line, stating, "We are delighted to offer our veterinary APIs and intermediates to the animal health industry. With our extensive experience in pharmaceutical manufacturing and commitment to quality, we strive to contribute to the well-being of animals worldwide. Our Fluralaner and Sarolaner products exemplify our dedication to innovation and excellence."
Huateng Pharma's veterinary product line is backed by state-of-the-art facilities, cutting-edge technology, and a team of highly skilled professionals. The company's comprehensive capabilities span the entire development and manufacturing process, from laboratory-scale production to commercial-scale operations. By leveraging their expertise and infrastructure, Huateng Pharma ensures the efficient and reliable supply of veterinary APIs and intermediates to meet the growing demands of the industry.
For more information about Huateng Pharma's veterinary product line or to inquire about partnership opportunities, please visit https://us.huatengsci.com/ or contact the sales team at sales@huatengusa.com.

Website: https://us.huatengsci.com
Email: sales@huatengusa.com
Zip code: 410205
Telephone: +86 731 89916275
Fax: + 86 731-82251112 EXT 818
Headoffice: Building E1, Lugu Corporation Plaza, High-Tech Industrial Development Zone, Changsha City, Hunan Province, P.R.China

Huateng Pharma is a leading Contract Development and Manufacturing Organization (CDMO) specializing in APIs and intermediates. With a steadfast commitment to quality and innovation, the company offers a comprehensive range of pharmaceutical solutions for human and veterinary health. Huateng Pharma's state-of-the-art facilities and experienced team ensure the highest standards of product development and manufacturing. For more information, please visit https://us.huatengsci.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Huateng Pharma's Featured Product Line: Veterinary API and Intermediates here

News-ID: 3353757 • Views:

More Releases from Hunan Huateng Pharmaceutical Co., Ltd.

Huateng Pharma Introduces New Cosmetic Actives to Meet Growing Demand for High-P …
Huateng Pharma, a global leader in specialty chemicals, has expanded its product portfolio to include a new line of high-quality cosmetic ingredients. The launch addresses the increasing demand for effective, safe, and readily available actives for modern skincare and personal care formulations. The new offerings are now available for immediate delivery and include several key ingredients: Diethylamino Hydroxybenzoyl Hexyl Benzoate (CAS 302776-68-7): A REACH-registered UVA filter that provides broad-spectrum sun protection. This
Huateng Pharma Highlights the Pharmaceutical Potential of N-Benzylhydroxylamine …
Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers and pharmaceutical developers worldwide. This compound has gained attention for its multifunctional properties and critical role in drug discovery and development. N-Benzylhydroxylamine Hydrochloride features a unique nitrogen-oxygen (N-O) functional group, which enables its wide-ranging applications in medicinal chemistry, including: Metal Chelation for Iron Overload Disorders: Its
Huateng Pharma to Showcase Extensive PEG Derivatives and CDMO Capabilities at CPHI Japan 2025
Huateng Pharma to Showcase Extensive PEG Derivatives and CDMO Capabilities at CP …
Changsha, China - 18 March 2025 - Hunan Huateng Pharmaceutical Co., Ltd., a global leader in PEG derivatives and CDMO services for APIs and intermediates, is pleased to announce its participation in CPHI Japan 2025. The company will exhibit its comprehensive product lines and cutting-edge capabilities at Booth No. 4X-06, located at Tokyo Big Sight, Tokyo, Japan, from April 9th to 11th, 2025. Huateng Pharma is dedicated to providing robust support
Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval
Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval
Changsha, China - Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma's dedication to meeting the highest regulatory standards and further strengthens its commitment to supporting

All 4 Releases


More Releases for Pharma

Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031. The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the